A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 686, Issue 1-2, 2010, Pages 1-8

  Araten, David J ^a,b   Martinez Climent, Jose A ^c   Perle, Mary Ann ^d   Holm, Eliana ^a   Zamechek, Leah ^a   DiTata, Kimberly ^a   Sanders, Katie J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genomic instability; GPI linked proteins; Hypermutability; Lymphoid neoplasms; PIG A gene; Plasma cell neoplasms

Indexed keywords

GENE PRODUCT; PROTEIN PIG A; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL DIVISION; CONTROLLED STUDY; CYTOGENETICS; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE MUTATION; GENETIC STABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR CLONING; PLASMACYTOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

CELL LINE, TUMOR; CLONE CELLS; FLOW CYTOMETRY; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, T-CELL; LYMPHOMA; MEMBRANE PROTEINS; MUTATION; NEOPLASMS, PLASMA CELL;

EID: 77649193092     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.11.012     Document Type: Article

References (35)

1. Albertini R.J., Nicklas J.A., O'Neill J.P., and Robison S.H. In vivo somatic mutations in humans: measurement and analysis. Ann. Rev. Genet. 24 (1990) 305-326
2. Green M.H.L., O'Neill J.P., and Cole J. Suggestions concerning the relationship between mutant frequency and mutation rate at the hprt locus in human peripheral T-lymphocytes. Mutat. Res. 334 (1995) 323-339
3. Vickers M.A., Hoy T., Lake H., Kyoizumi S., Boyse J., and Hewitt M. Estimation of mutation rate at human glycophorin A locus in hematopoietic stem cell progenitors. Environ. Mol. Mutagen. 39 (2002) 333-341
4. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51 (1991) 3075-3079
5. Hahn W.C., and Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 347 (2002) 1593-1603
6. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Changsheng L., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., and Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
7. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., and Loeb L.A. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 18238-18242
8. Seshadri R., Kutlaca R.J., Trainor K., Matthews C., and Morley A.A. Mutation rate of normal and malignant human lymphocytes. Cancer Res. 47 (1987) 407-409
9. Kendal W.S., and Frost P. Pitfalls and practice of Luria-Delbruck fluctuation analysis: a review. Cancer Res. 48 (1988) 1060-1065
10. Rossman T.G., Goncharova E.I., and Nadas A. Modeling and measurement of the spontaneous mutation rate in mammalian cells. Mutat. Res. 328 (1995) 21-30
11. Glaab W.E., and Tindall K.R. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 18 (1997) 1-8
12. Lin Y.W., Perkins J.J., Zhang Z., and Aplan P.D. Distinct mechanisms lead to HPRT gene mutations in leukemic cells. Genes Chromosomes Cancer 39 (2004) 311-323
13. Bachl J., Dessing M., Olsson C., vonBorstel R.C., and Steinberg C. An experimental solution for the Luria-Delbruck flucutation problem in measuring hypermutation rates. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6847-6849
14. Nicolas J.F., Jakob H., and Jacob F. Metabolic cooperation between mouse embryonal carcinoma cells and their differentiated derivatives. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 3292-3296
15. Araten D.J., Golde D.W., Zhang R.H., Thaler H.T., Gargiulo L., Notaro R., and Luzzatto L. A quantitative measurement of the human somatic mutation rate. Cancer Res. 65 (2005) 8111-8117
16. Hillmen P., Bessler M., Mason P.J., Watkins W.M., and Luzzatto L. Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 5272-5276
17. Miyata T., Takeda J., Iida Y., Yamada N., Inoue N., Takahashi M., Maeda K., Kitani T., and Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 259 (1993) 1318-1320
18. Rosse W.F., and Ware R.E. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 86 (1995) 3277-3286
19. Luzzatto L., and Nafa K. Genetics of PNH. In: Young N., and Moss J. (Eds). PNH and the GPI-linked Proteins (2000), Academic Press, San Diego 21-47
20. Carrel L., and Willard H. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434 (2005) 400-404
21. Araten D.J., Bessler M., McKenzie S., Castro-Malaspina H., Childs B.H., Boulad F., Karadimitris A., Notaro R., and Luzzatto L. Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones. Leukemia 16 (2002) 2243-2248
22. Keller P., Payne J.L., Tremml G., Greer P.A., Gaboli M., Pandolfi P.P., and Bessler M. FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow. J. Exp. Med. 194 (2001) 581-590
23. Araten D., Nafa K., Pakdeesuwan K., and Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5209-5214
24. Chen R., Eshleman J.R., Brodsky R.A., and Medof M.E. Glycosylphosphatidylinositol-anchored protein deficiency as a marker of mutator phenotypes in cancer. Cancer Res. 61 (2001) 654-658
25. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marín M., Rosenwald A., Sugimoto K., Wheat L., Karran E., García J., Sanchez L., Prosper F., Staudt L., Pinkel D., Dyer M., and Martinez-Climent J. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109 (2007)
26. Rubio-Moscardo F., Blesa D., Mestre C., Siebert R., Balasas T., Benito A., Rosenwald A., Climent J., Martinez J.I., Schilhabel M., Karran E.L., Gesk S., Esteller M., deLeeuw R., Staudt L.M., Fernandez-Luna J.L., Pinkel D., Dyer M., and Martinez-Climent J.A. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106 (2005) 3214-3222
27. Araten D.J., and Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 108 (2006) 734-736
28. Brodsky R., Mukhina G., Nelson K., Lawrence T., Jones R., and Buckley J. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood 93 (1999) 1749-1756
29. Bhattacharyya N., Skandalis A., Ganesh A., Groden J., and Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6319-6323
30. Tashima Y., Taguchi R., Murata C., Ashida H., Kinoshita T., and Maeda Y. PGAP2 is essential for correct processing and stable expression of GPI-anchored proteins. Mol. Biol. Cell 17 (2006) 1410-1420
31. Hu R., Mukhina G.L., Piantadosi S., Barber J.P., Jones R.J., and Brodsky R.A. PIG-A mutations in normal hematopoiesis. Blood 105 (2005) 3848-3854
32. Rawstron A.C., Rollinson S.J., Richards S., Short M.A., English A., Morgan G.J., Hale G., and Hillmen P. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br. J. Haematol. 107 (1999) 148-153
33. Ware R.E., Pickens C.V., DeCastro C.M., and Howard T.A. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp. Hematol. 29 (2001) 1403-1409
34. Hu R., Mukhina G., Lee S., Jones R., Englund P., Brown P., Sharkis S., Buckley J., and Brodsky R. Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma. Exp. Hematol. 37 (2009) 423-434
35. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., Su X., Pui C.H., Relling M.V., Evans W.E., Shurtleff S.A., and Downing J.R. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 (2007) 758-764